Summary of your 'study carrel' ============================== This is a summary of your Distant Reader 'study carrel'. The Distant Reader harvested & cached your content into a collection/corpus. It then applied sets of natural language processing and text mining against the collection. The results of this process was reduced to a database file -- a 'study carrel'. The study carrel can then be queried, thus bringing light specific characteristics for your collection. These characteristics can help you summarize the collection as well as enumerate things you might want to investigate more closely. This report is a terse narrative report, and when processing is complete you will be linked to a more complete narrative report. Eric Lease Morgan Number of items in the collection; 'How big is my corpus?' ---------------------------------------------------------- 36 Average length of all items measured in words; "More or less, how big is each item?" ------------------------------------------------------------------------------------ 32809 Average readability score of all items (0 = difficult; 100 = easy) ------------------------------------------------------------------ 46 Top 50 statistically significant keywords; "What is my collection about?" ------------------------------------------------------------------------- 35 plasma 10 COVID-19 6 protein 6 patient 5 convalescent 5 cell 4 dna 4 SARS 3 study 3 blood 2 virus 2 viral 2 result 2 increase 2 high 2 cancer 2 airway 2 RNA 2 PCR 2 MSC 2 ELISA 2 CRC 1 western 1 werden 1 von 1 vesicle 1 und 1 treatment 1 time 1 summary 1 spanish 1 size 1 sample 1 rbd 1 proteomic 1 product 1 platelet 1 pathogen 1 myeloma 1 multiple 1 method 1 mefloquine 1 mediator 1 marker 1 level 1 isolate 1 introduction 1 human 1 horse 1 heparin Top 50 lemmatized nouns; "What is discussed?" --------------------------------------------- 3566 ev 3437 cell 3051 plasma 2178 patient 1861 protein 1424 % 1285 method 1277 study 1146 result 1135 blood 963 disease 924 treatment 917 cancer 915 analysis 882 vesicle 814 factor 742 sample 725 effect 713 level 701 platelet 682 exosome 651 conclusion 647 antibody 624 therapy 598 concentration 597 time 585 expression 558 virus 537 marker 512 control 498 assay 493 group 477 introduction 473 size 453 activity 442 system 429 donor 426 product 422 day 416 response 415 tumour 413 type 407 datum 405 mouse 403 biomarker 401 infection 399 role 391 tissue 380 activation 377 p Top 50 proper nouns; "What are the names of persons or places?" -------------------------------------------------------------- 693 EV 560 Summary 452 RNA 430 COVID-19 318 der 306 EVs 279 MSC 252 SARS 249 miRNA 201 University 196 C 190 NTA 183 miRNAs 169 von 169 USA 169 APC 158 Extracellular 157 CD63 149 CoV-2 147 al 140 b 137 MS 133 SEC 127 CD9 125 exosomes 124 et 120 PCR 112 mg 108 werden 108 Plasma 104 ELISA 102 VIII 102 PA 101 S 99 Introduction 99 HIV 99 F 99 CD81 97 TEM 97 . 91 und 89 National 86 Exosomes 83 T 79 A 78 II 78 Health 78 DNA 76 Research 76 Institute Top 50 personal pronouns nouns; "To whom are things referred?" ------------------------------------------------------------- 1975 we 696 it 211 they 163 i 95 them 51 us 35 he 20 itself 16 themselves 12 you 10 one 2 she 2 ourselves 2 me 2 a1-antitrypsin 1 und 1 sevs 1 ofvwd 1 nsp(+)-evs 1 myself 1 mrnas 1 mir-1202 1 microev 1 mg 1 j824 1 him 1 ccrcc 1 casp3-/mice 1 casp3-/-mice 1 aptt Top 50 lemmatized verbs; "What do things do?" --------------------------------------------- 14486 be 2339 have 2031 use 981 show 736 derive 651 increase 569 compare 562 isolate 558 associate 526 include 499 induce 458 find 450 identify 448 treat 448 demonstrate 446 base 414 perform 413 develop 411 follow 377 determine 364 provide 364 detect 354 suggest 344 do 333 reduce 327 measure 307 contain 304 observe 298 obtain 298 characterize 288 die 286 report 281 investigate 266 evaluate 262 reveal 259 analyse 250 result 246 express 243 circulate 238 assess 236 relate 235 bind 233 confirm 232 cause 228 produce 226 indicate 224 lead 220 require 220 know 219 collect Top 50 lemmatized adjectives and adverbs; "How are things described?" --------------------------------------------------------------------- 1157 - 1065 not 911 high 750 also 712 human 657 convalescent 617 extracellular 586 clinical 544 different 501 well 498 specific 491 other 489 low 483 such 468 however 412 more 400 small 370 only 370 most 368 therapeutic 363 anti 349 as 345 significantly 336 severe 328 viral 323 normal 319 non 309 further 307 first 298 early 294 significant 287 potential 285 immune 282 acute 277 new 274 large 265 molecular 250 inflammatory 247 several 246 healthy 245 novel 241 single 236 free 233 important 221 endothelial 219 multiple 208 cellular 207 present 202 total 200 positive Top 50 lemmatized superlative adjectives; "How are things described to the extreme?" ------------------------------------------------------------------------- 104 most 55 least 42 good 39 high 30 Most 19 large 16 low 15 great 10 cfDNA 4 strong 4 small 4 poor 3 late 3 bad 2 sick 2 fast 2 early 2 deadly 2 big 1 ® 1 slight 1 short 1 severe 1 pure 1 new 1 miR-193b 1 higl) 1 alpha-2antiplasmin 1 RGPIN2014 Top 50 lemmatized superlative adverbs; "How do things do to the extreme?" ------------------------------------------------------------------------ 266 most 35 least 5 well 3 cfdna 2 highest 1 worst Top 50 Internet domains; "What Webbed places are alluded to in this corpus?" ---------------------------------------------------------------------------- 7 links.lww.com 7 doi.org 2 links.lww 2 creativecommons.org 1 www.uscovidplasma.org 1 www.ukev.org.uk 1 www.thingiverse 1 www.matrixscience 1 www.chictr.org.cn 1 www.abrf.org 1 orcid.org 1 isbtweb.org 1 data.mendeley 1 creat 1 covidplasma.org 1 ccpp19.org Top 50 URLs; "What is hyperlinked from this corpus?" ---------------------------------------------------- 3 http://links.lww.com/CCM/F805 3 http://doi.org/10.1101/2020.06.21.20132944 3 http://doi.org/10.1038/s41598-020-74288-2 2 http://links.lww.com/CCM/F804 2 http://links.lww.com/ 2 http://links.lww 2 http://creativecommons.org/licenses/by/4.0/ 1 http://www.uscovidplasma.org 1 http://www.ukev.org.uk/public-engagementmaterials/ 1 http://www.thingiverse 1 http://www.matrixscience 1 http://www.chictr.org.cn 1 http://www.abrf.org/index.cfm/ 1 http://orcid.org/0000-0003-3223-8374 1 http://isbtweb.org/coronaoutbreak/covid-19 1 http://doi.org/10.1371/journal.pone.0236754 1 http://data.mendeley 1 http://creat 1 http://covidplasma.org/ 1 http://ccpp19.org/ Top 50 email addresses; "Who are you gonna call?" ------------------------------------------------- 1 shikata@brs.kyushu-u.ac.jp 1 jfdez@clinic.cat Top 50 positive assertions; "What sentences are in the shape of noun-verb-noun?" ------------------------------------------------------------------------------- 7 cell derived evs 7 samples were then 6 treatment reduced mortality 5 evs were also 5 evs were then 4 cell derived vesicles 4 evs are able 4 evs were able 4 exosomes are small 4 expression was significantly 4 levels were not 4 levels were significantly 4 plasma is not 4 plasma is safe 3 cells did not 3 cells showed more 3 cells were then 3 disease is still 3 evs are highly 3 evs did not 3 evs were significantly 3 plasma derived intermediates 3 proteins were significantly 3 results are consistent 3 samples were also 3 studies are underway 3 treatment did not 3 treatment is not 3 treatment was also 3 vesicles including exosomes 2 % are tenascin 2 analysis determine association 2 analysis following ev 2 analysis was then 2 antibodies were not 2 blood derived products 2 cancer derived evs 2 cells are capable 2 cells derived exosomes 2 cells is critical 2 cells is difficult 2 cells is essential 2 cells is still 2 cells using differential 2 cells were mainly 2 cells were subsequently 2 disease is poorly 2 diseases is essential 2 effect is mainly 2 effect was not Top 50 negative assertions; "What sentences are in the shape of noun-verb-no|not-noun?" --------------------------------------------------------------------------------------- 2 levels were not different 1 analyses showed no medical 1 analysis showed no significant 1 analysis showed no structural 1 analysis were no hepada 1 antibodies is not enough 1 antibodies were not detectable 1 cells is not fully 1 cells showed no viral 1 concentration were not detectable 1 concentrations showed no relationship 1 disease is not well 1 diseases were not reactive 1 effect has not yet 1 effect was not detectable 1 evs does not significantly 1 evs was not significantly 1 evs were not positive 1 exosomes had no effect 1 levels are not well 1 levels were not further 1 patient had no rise 1 patient has no further 1 patients had no acute 1 patients is not easy 1 patients show no detectable 1 plasma had no minimum 1 plasma had no significant 1 plasma is not benign 1 plasma is not immediately 1 platelets was not different 1 results do not lady 1 therapy is not fully 1 therapy is not helpful 1 treatment did not dramatically 1 treatment did not substantially 1 treatment is not available 1 treatment is not necessarily 1 treatment showed no receptor 1 treatments are not available A rudimentary bibliography -------------------------- id = cord-261653-0vtghtp7 author = Andersen, Kylie J. title = Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors date = 2020-09-21 keywords = COVID-19; plasma summary = Thus, the present narrative overviews the strategy developed by our team to identify and recruit COVID-19 survivors to donate convalescent plasma at the Mayo Clinic Blood Donor Center in Rochester, Minnesota. Rochester, Minnesota required a strategy to interface with the community of recovering COVID-19 patients and recruit eligible convalescent plasma donors. Overall, this recruitment strategy utilized a simple survey, an algorithm for triaging donors, a workflow for connecting donors with Mayo Clinic Blood Donor Center, a team of physician navigators (including medical students) to screen eligible donors, and a support center for donor questions. Our web-based recruitment survey and all e-mail communications to interested potential donors contained the e-mail address for our convalescent plasma service center. The service center team used available resources from the US FDA, Mayo Clinic, and the blood banking community to support questions regarding donor eligibility and COVID-19 testing. doi = 10.1016/j.mayocp.2020.09.021 id = cord-328352-l1q4uvxl author = Borlongan, Mia C. title = The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy date = 2020-08-25 keywords = COVID-19; plasma; spanish summary = doi = 10.1177/0963689720940719 id = cord-262776-6k7tcgfs author = Burnouf, Thierry title = Assessment of the viral safety of antivenoms fractionated from equine plasma date = 2004-09-30 keywords = RNA; antivenom; horse; plasma; viral; virus summary = doi = 10.1016/j.biologicals.2004.07.001 id = cord-266147-s8rxzm0t author = Burnouf, Thierry title = Modern Plasma Fractionation date = 2007-03-28 keywords = FVIII; plasma; product; protein; treatment; viral summary = doi = 10.1016/j.tmrv.2006.11.001 id = cord-324908-ptlpsnfo author = Cao, Huiling title = Convalescent plasma: possible therapy for novel coronavirus disease 2019 date = 2020-05-02 keywords = Ebola; convalescent; plasma summary = 16 Public Health of England and the International Severe Acute Respiratory and Emerging Infection Consortium 17 put forward that convalescent plasma could be a promising specific treatment for serious Middle East respiratory syndrome (MERS), and further evaluation is needed in human clinical trials. Although many studies have reported the efficacy and safety of convalescent plasma infusion in the treatment of various infections, due to the lack of large-scale, randomized, well-designed, and prospective clinical trials, we tend to consider convalescent plasma as an "empirical" therapy. Mortality in the treatment group was significantly lower than in the nontreatment group ( controlled trial reported that patients who received immune plasma and standard care for severe influenza showed a nonsignificant reduction in the mortality rate. In conclusion, the transfusion of up to 500 mL of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed Ebola virus infection was not associated with a significant improvement in survival. doi = 10.1111/trf.15797 id = cord-349031-tbof9yqi author = Chen, Shiu-Jau title = Novel Antiviral Strategies in the Treatment of COVID-19: A Review date = 2020-08-20 keywords = COVID-19; MSC; SARS; patient; plasma summary = doi = 10.3390/microorganisms8091259 id = cord-274150-ukdha3ap author = Choi, Jun Yong title = Convalescent Plasma Therapy for Coronavirus Disease 2019 date = 2020-09-03 keywords = COVID-19; convalescent; plasma summary = Given its rapid acquisition, convalescent plasma therapy has been considered as an emergency intervention in several pandemics, including the Spanish flu, severe acute respiratory syndrome coronavirus (SARS-CoV-1), and West Nile virus, and more recently, Ebola virus [7] [8] [9] . Although large-scale randomized controlled trials have not yet been performed, and most studies did not evaluate neutralizing activities of used convalescent plasma, previous experiences on convalescent plasma therapy for the treatment of emerging infectious diseases provide us with important historical precedents that this intervention might be useful for confronting the COVID-19 epidemics. To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID19 , an open-label, multicenter, randomized clinical trial was performed in seven medical centers in Wuhan, China. Some patients who recover from viral diseases may not have high titers of neutralizing antibodies, which are crucial for the effectiveness of convalescent plasma therapy [13, 14] . doi = 10.3947/ic.2020.52.3.307 id = cord-010328-uxpedpz8 author = Ciencewicki, Jonathan M. title = Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products date = 2020-04-22 keywords = hav; plasma summary = In this study, source plasma from donation centers in various locations of the Southwestern quarter of the United States was surveyed for antibody titers to hepatitis A virus (HAV), measles virus (MeV), and cytomegalovirus (CMV). Safety measures implemented nearly two decades ago-collaborative, industry-wide epidemiological surveillance of the donor population, judicious selection of donors, rigorous testing of plasma by serological and molecular (e.g., nucleic acid testing) methods and validation of manufacturing methods for virus clearance capacity-provide a high degree of confidence that IG products, regardless of plasma origin, safely deliver a diverse, natural combination of human polyclonal antibodies 1,2 . The analyses of individual units originating from select pools served to demonstrate that a number of centers in the US Southwest are capable of consistently generating plasma with elevated anti-HAV Ig titers. doi = 10.1038/s41598-020-63794-y id = cord-321697-yua3apfi author = Crigna, Adriana Torres title = Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope? date = 2020-10-29 keywords = CRC; cancer; cell; dna; increase; patient; plasma; study summary = This article highlights the involvement of circulating CFNAs in local and systemic processes dealing with the question, whether specific patterns of CFNAs in blood, their detection, quantity and quality (such as their methylation status) might be instrumental to predict a disease development/progression and could be further utilised for accompanying diagnostics, targeted prevention, creation of individualised therapy algorithms, therapy monitoring and prognosis. Especially severe, prolonged and/ or chronic stress of any origin such as exercise-induced oxidative stress [22] (see "Physical activity and exercise-induced oxidative stress" section), hormonal stress [23] , emotional stress and psychological burden [24] [25] [26] [27] as well as metabolic stress, e.g. in diabetes mellitus [28, 29] (see also below "Association between diabetes mellitus and carcinogenesis: diagnostic and therapeutic potential of cell-free nucleic acids" section) and hyperhomocysteinaemia [30, 31] amongst others, is associated with highly increased ROS production and insufficient repair capacity-both linked to oxidative damage of mitochondria and consequent mitochondrial dysfunction leading to the development of cardiovascular impairments [32] [33] [34] , neuro/degenerative pathologies [34] [35] [36] [37] , impaired healing [34] and malignant cell transformation [34, [38] [39] [40] [41] [42] . doi = 10.1007/s13167-020-00226-x id = cord-351328-ly72scru author = Epstein, Jay title = Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma date = 2020-05-14 keywords = plasma summary = doi = 10.1111/vox.12939 id = cord-305074-wz17u4e7 author = Fernandez, Javier title = Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 Infection date = 2020-08-24 keywords = ICU; exchange; plasma summary = doi = 10.1097/ccm.0000000000004613 id = cord-319013-oytqcifa author = Focosi, Daniele title = Convalescent Plasma Therapy for COVID-19: State of the Art date = 2020-08-12 keywords = COVID-19; SARS; convalescent; patient; plasma summary = In the first retrospective, randomized controlled trial published to date, 39 patients in New York with severe COVID-19 were transfused with 2 units of ABO-type matched CP with anti-Spike antibody titers of Ն1:320 (measured by a two-step Spike proteindirected ELISA). CP (9 to 13 ml/kg from donors with S-RBD IgG titer of Ն1:640) was associated with a negative SARS-CoV-2 PCR test at 72 h in 87.2% of the CP group versus 37.5% of the BSC group, but clinical improvement at 28 days was statistically different only in patients with severe, but not in life-threatening, disease (104) . Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 doi = 10.1128/cmr.00072-20 id = cord-271764-um001ffd author = Garraud, Olivier title = Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials? date = 2020-06-27 keywords = COVID-19; plasma summary = doi = 10.1016/j.transci.2020.102858 id = cord-304616-k92fa15l author = Izes, Aaron M. title = Assay validation and determination of in vitro binding of mefloquine to plasma proteins from clinically normal and FIP-affected cats date = 2020-08-05 keywords = fip; mefloquine; plasma; protein summary = doi = 10.1371/journal.pone.0236754 id = cord-322714-s0wge7o4 author = Joyner, Michael J. title = Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients date = 2020-07-19 keywords = COVID-19; plasma summary = doi = 10.1016/j.mayocp.2020.06.028 id = cord-305130-vz72ldbo author = Keil, Shawn D. title = Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light‐based photochemical treatment date = 2020-05-14 keywords = SARS; plasma summary = doi = 10.1111/vox.12937 id = cord-294585-dl5v9p50 author = Klein, H. G. title = Pathogen‐reduction methods: advantages and limits date = 2009-02-13 keywords = blood; pathogen; plasma; virus summary = However, because blood contains numerous labile proteins and fragile cells, and because there is a wide array of potentially infectious agents, no single method of pathogen-inactivation will likely preserve all blood components, yet effectively remove all viruses, bacteria, spores, protozoa and prions. Riboflavin/ultraviolet light treatment has been evaluated in preclinical studies and found to result in reduction of infectivity by many pathogens including west Nile virus, intracellular HIV, bacteria and protozoa. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients doi = 10.1111/j.1751-2824.2009.01224.x id = cord-284582-xwedgllw author = Korabecna, M. title = Cell-free DNA in plasma as an essential immune system regulator date = 2020-10-15 keywords = cell; dna; plasma summary = doi = 10.1038/s41598-020-74288-2 id = cord-335316-x2t5h5gu author = Madariaga, M. L. L. title = Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial date = 2020-06-23 keywords = COVID-19; antibody; plasma; rbd summary = doi = 10.1101/2020.06.21.20132944 id = cord-277811-j58qvyum author = Mehrani, Hossein title = Plasma proteomic profile of sulfur mustard exposed lung diseases patients using 2-dimensional gel electrophoresis date = 2011-01-07 keywords = patient; plasma; protein summary = doi = 10.1186/1559-0275-8-2 id = cord-280221-s6oxq772 author = Montelongo-Jauregui, Daniel title = Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease date = 2020-08-12 keywords = COVID-19; plasma summary = doi = 10.1371/journal.ppat.1008735 id = cord-270908-9snyt2n1 author = PERSSON, C. G. A. title = Airway permeability date = 2006-04-27 keywords = absorption; airway; epithelial; plasma summary = doi = 10.1111/j.1365-2222.1995.tb00022.x id = cord-326176-n0xo3e53 author = Patel, Reema T. title = Multiple myeloma in 16 cats: a retrospective study date = 2008-03-05 keywords = cat; cell; multiple; myeloma; plasma summary = doi = 10.1111/j.1939-165x.2005.tb00059.x id = cord-006192-bqwchhwk author = Persson, Carl G. A. title = Plasma exudation and asthma date = 1988 keywords = airway; bronchial; effect; mediator; plasma summary = doi = 10.1007/bf02714025 id = cord-352985-5ccrkfsa author = Putter, Jeffrey S. title = An Update on COVID-19 Infection Control Measures, Plasma-Based Therapeutics, Corticosteroid Pharmacotherapy and Vaccine Research date = 2020-09-04 keywords = CCP; coronavirus; plasma summary = doi = 10.1016/j.transci.2020.102934 id = cord-018845-r88bhiac author = Sachs, U. J. H. title = Gewinnung, Herstellung und Lagerung von Blut und Blutkomponenten date = 2010-11-21 keywords = Blut; Blutspende; Erythrozyten; Gewinnung; Plasma; Regel; Spender; Thrombozyten; der; die; und; von; werden summary = doi = 10.1007/978-3-642-12765-6_16 id = cord-282252-07uzz649 author = Sahu, Kamal Kant title = Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID‐19 date = 2020-05-21 keywords = convalescent; plasma summary = The basic concept for use of convalescent plasma in COVID-19 is as a delivery system for viral neutralizing antibodies, that is to confer passive immunity. Considering the aforementioned limitations and the potential risks, appropriate triage systems should be utilized; hence, plasma therapy use is currently restricted only to critically ill patients. The FDA recommends two clinical indications for the current usage of convalescent plasma therapy in COVID-19 patients(12) Scenario A (Severe disease) which is defined as one or more of the following: On April 3, 2020, the FDA cleared the path for the use of this potential lifesaving therapy under any of the following three routes[1] enrollment in a clinical trial, [2] via the national expanded access treatment protocol, and [3] under a single patient emergency investigational new drug application (eIND). Lacking a vaccine and with limited antiviral options against SARS-CoV-2, this is an ideal time to try convalescent plasma therapy in COVID-19 patients. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients doi = 10.1002/jmv.26047 id = cord-018142-xt71w4nr author = Samy Modeliar, S. title = Thrombotic Microangiopathy Syndrome in the ICU date = 2006 keywords = HUS; TMA; TTP; plasma summary = doi = 10.1007/3-540-33396-7_20 id = cord-336177-p7b7yw28 author = Selvi, Valeria title = Convalescent Plasma: A Challenging Tool to Treat COVID-19 Patients—A Lesson from the Past and New Perspectives date = 2020-09-22 keywords = COVID-19; SARS; convalescent; plasma summary = doi = 10.1155/2020/2606058 id = cord-329228-yjvw2ee1 author = Shikata, N. title = Multi-layered network structure of amino acid (AA) metabolism characterized by each essential AA-deficient condition date = 2006-10-13 keywords = acid; amino; plasma summary = doi = 10.1007/s00726-006-0412-0 id = cord-294684-wfsdjs1f author = Vesnaver, Elisabeth title = Barriers and enablers to source plasma donation by gay, bisexual and other men who have sex with men under revised eligibility criteria: protocol for a multiple stakeholder feasibility study date = 2020-11-02 keywords = blood; donation; gbmsm; plasma summary = doi = 10.1186/s12961-020-00643-4 id = cord-323656-bzefn894 author = Yoo, Jin-Hong title = Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying date = 2020-04-06 keywords = plasma summary = doi = 10.3346/jkms.2020.35.e150 id = cord-018492-d34tyar7 author = Zaza, Mouayyad title = Dried Plasma date = 2019-05-06 keywords = FFP; dry; plasma summary = doi = 10.1007/978-3-030-20820-2_8 id = cord-284208-8fsqgkw5 author = Zolla, Lello title = Proteomics studies reveal important information on small molecule therapeutics: a case study on plasma proteins date = 2008-11-07 keywords = drug; plasma; protein; proteomic summary = doi = 10.1016/j.drudis.2008.09.013 id = cord-006860-a3b8hyyr author = nan title = 40th Annual Meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung) date = 1996 keywords = ADP; APC; APTT; DVT; ELISA; FXII; Germany; HUVEC; INR; LMWH; Leiden; PAI; PCR; STA; TEG; VIII; activity; blood; cell; dna; factor; hat; heparin; high; increase; level; patient; plasma; platelet; protein; result; study; time summary = Dept of Pediatrics, University Hospitals Kiel and Mtinster, Germany Resistance to activated protein C (APCR), in the majority of cases associated with the Arg 506 Gin point mutation in the factor V gene is present in more than 50 % of patients < 60 years of age with unexplained thrombophilia. The regular APC resistance test is not applicable to plasma from Orally anticoagulated (OAC) or heparinized patients due to decreased levels of vitamin K-dependent clotting factors and to thrombin inhibition by antithrombin, respectively. On admission an extensive coagulation screen yielded the following results (n/normal, t/elevated, I/reduced, +/positive, -/negative): PT t, aPTT t, Tr n, factor II, V, VIII n, factor VII, IX, XI, XII /,, fibrinogan t, ATIII n, protein C, S *, activated protein C sensitivity ratio 1.92 ($), FV-Leidenmutation PCR -, fibrinolytic system n, TAT t, Ft÷2 t, lupus anticoagulant +, heparin induced platelet antibodies +; no diagnosis of a specific autoimmuna disorder could be made. doi = 10.1007/bf00641048 id = cord-031907-ilhr3iu5 author = nan title = ISEV2020 Abstract Book date = 2020-07-15 keywords = CD63; CD81; CD9; CDC; CRC; CSF; ELISA; Exo; Extracellular; GBM; HER2; HIV; Health; Institute; L1CAM; MDA; MSC; NIH; NTA; Nanoparticle; National; PCR; RNA; Research; SEC; TEM; Tau; USA; University; analysis; cancer; cell; conclusion; dna; exosome; expression; high; human; introduction; isolate; marker; method; patient; plasma; protein; result; sample; size; study; summary; vesicle; western summary = L.M., and the National Institutes of Health (R35GM119623) to T.R.G. The addition of a size exclusion chromatography step to various urinary extracellular vesicle concentrating methods reveals differences in the small RNA profile Introduction: Urinary extracellular vesicles (EVs) and their RNA cargo are a novel source of biomarkers for various diseases, however non-vesicular RNA (e.g. associated with proteins) is also present within urine. We then evaluated efficiency of heart targeting for eAAV9 or eAAV6 and standard AAV9 or AAV6 encoding for EGFP, mCherry or firefly luciferase in different human cell lines in vitro, in black mouse and in passive immunity nude mouse model in vivo using flow cytometry, confocal microscopy, Langendorff perfusion system and Methods: HLHS patients (n = 3) after Glenn procedure and swine (n = 3) after PAB were given RV injections of allogeneic/xenogeneic MSCs. Donor-specific, HLA-I+, exosomes were isolated from plasma. doi = 10.1080/20013078.2020.1784511